Hemant Surgical Industries Limited convened its Board of Directors meeting on May 15, 2026, and approved the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 2:30 p.m. and concluded at 4:05 p.m., with the results also made available on the company's website. Statutory Auditors A D V & Associates (FRN: 128045W) issued unmodified audit opinions on both standalone and consolidated financial statements.

Q4 Performance Highlights

Hemant Surgical Industries posted a strong quarter, with Q4 revenue reaching 1.7B Rupees compared to 576M Rupees in the same period last year. Net profit for Q4 rose sharply to 128M Rupees from 49M Rupees year-on-year. EBITDA for the quarter came in at 158M Rupees versus 55M Rupees in the corresponding prior-year period, while EBITDA margin stood at 9.5% compared to 9.63% year-on-year.

Standalone Financial Performance

Hemant Surgical Industries delivered a strong standalone performance for FY26, with revenue from operations rising sharply to ₹23,098.71 lakhs from ₹10,652.66 lakhs in the previous year. Net profit for the full year more than doubled to ₹1,823.34 lakhs compared to ₹813.21 lakhs in FY25. The following table summarises the standalone profit and loss performance:

Consolidated Financial Performance

On a consolidated basis, which includes wholly owned subsidiary Solar Opto Medics Private Limited, Hemant Surgical Industries reported revenue from operations of ₹23,180.66 lakhs for FY26, compared to ₹10,663.69 lakhs in FY25. Consolidated net profit for the year stood at ₹1,819.10 lakhs, up from ₹804.10 lakhs in the prior year. The subsidiary contributed total revenues of ₹46.38 lakhs for the half year ended March 31, 2026.

Balance Sheet Highlights

The standalone balance sheet as at March 31, 2026 reflects significant expansion, with total assets growing to ₹27,400.73 lakhs from ₹14,764.34 lakhs a year earlier. Shareholders' funds strengthened considerably, with share capital at ₹1,303.84 lakhs and reserves and surplus rising to ₹11,412.67 lakhs from ₹5,255.03 lakhs. Cash and cash equivalents on a standalone basis stood at ₹4,383.11 lakhs, up from ₹945.69 lakhs. On a consolidated basis, total assets stood at ₹27,426.11 lakhs as at March 31, 2026, compared to ₹14,830.88 lakhs in the prior year.

Capital Raise and Fund Utilisation

During the half year ended March 31, 2026, Hemant Surgical Industries raised ₹6,152.71 lakhs through the issue of 25,98,400 equity shares of ₹10 each at ₹197 per share (including a premium of ₹187 per share) and 20,99,200 warrants at ₹197 per warrant (on receipt of 25% i.e. ₹49.25 per warrant), each convertible into one equity share on payment of the balance 75% (₹147.75) within 18 months from the date of allotment. The utilisation of proceeds as at March 31, 2026 is detailed below:

Out of total proceeds of ₹6,152.71 lakhs, the company has utilised ₹4,663.63 lakhs for intended purposes, with ₹1,489.07 lakhs lying in the company's bank account. An additional ₹3,101.57 lakhs is expected to be received at the time of conversion of the outstanding warrants. The trading window for dealing in Hemant Surgical Industries' securities, which had been closed from April 01, 2026, for all designated persons, will reopen 48 hours after the declaration of these audited results to the stock exchange.

Hemant Surgical Industries Limited has submitted its quarterly compliance certificate to BSE Limited, confirming that the company's entire shareholding remains in dematerialised form for the quarter ended March 31, 2026.

Regulatory Compliance Certificate

The company filed its certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 on April 7, 2026. The submission confirms that the regulation is not applicable to the company due to specific compliance conditions being met.

Share Holding Status

The certificate confirms two key compliance aspects for the quarter:

• The entire holding of the company's shares remains in demat form
• No requests for rematerialisation were received from any members during the quarter

These conditions render Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 not applicable to the company for this reporting period.

Registrar Confirmation

Bigshare Services Pvt. Ltd., serving as the company's registrar and share transfer agent, issued the compliance certificate on April 6, 2026. The certificate was signed by Akash Shamal, Authorised Signatory of Bigshare Services.

Management Submission

The filing was submitted to BSE Limited by Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited. The digital submission was completed on April 7, 2026, ensuring timely regulatory compliance.

This compliance filing demonstrates the company's adherence to SEBI regulations regarding dematerialised shareholding and maintains transparency with regulatory authorities and stakeholders.